Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.63 |
| ▸ | CHUK | O15111 | 10/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | HNF4A | P41235 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687001 | 1.00 | IKBKB (0.63) | IKBKBCHUKPDPK1ADRB1KEAP1 | |
| SCHEMBL3802579 | 0.78 | IKBKB (1.00) | IKBKBCHUKPDPK1 | |
| Cinnamic Acid SCHEMBL8595083 | 0.77 | PDPK1 (0.68) | IKBKBCHUKPDPK1KEAP1SIRT2 | |
| Cinnamic Acid SCHEMBL8595085 | 0.77 | PDPK1 (0.68) | IKBKBCHUKPDPK1KEAP1SIRT2 | |
| SCHEMBL4689422 | 0.77 | IKBKB (0.97) | IKBKBCHUKPDPK1 | |
| SCHEMBL28335692 | 0.75 | IKBKB (0.60) | IKBKBCHUKPDPK1ADRB1KEAP1 | |
| SCHEMBL4689165 | 0.74 | IKBKB (0.91) | IKBKBCHUKPDPK1KEAP1 | |
| SCHEMBL29898213 | 0.73 | IKBKB (0.62) | IKBKBCHUKPDPK1ADRB1KEAP1 | |
| SCHEMBL4687705 | 0.72 | IKBKB (0.78) | IKBKBCHUKPDPK1ADRB1KEAP1 | |
| SCHEMBL552112 | 0.72 | IKBKB (0.60) | IKBKBCHUKPDPK1ADRB1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | claimed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885PDPK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.